[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 27 of about 27
1. Sengul E, Dervisoglu E, Kus E, Ciftci E, Ercin C, Yilmaz A: Acute lymphoblastic leukaemia presenting with acute renal failure: report of two cases. J Pak Med Assoc; 2008 Sep;58(9):512-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukaemia presenting with acute renal failure: report of two cases.
  • Here we report two patients with acute lymphoblastic leukaemia presenting with acute renal failure due to leukaemic infiltration.
  • The first patient died before the administration of specific therapy for leukaemia, whereas the second case recovered after chemotherapy.
  • She was discharged without necessitating dialysis therapy.
  • [MeSH-major] Acute Kidney Injury / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Fatal Outcome. Humans. Male. Middle Aged. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Pak Med Assoc. 2008 Dec;58(12):719
  • (PMID = 18846803.001).
  • [ISSN] 0030-9982
  • [Journal-full-title] JPMA. The Journal of the Pakistan Medical Association
  • [ISO-abbreviation] J Pak Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


2. Inaba H, Jones DP, Gaber LW, Shenep JL, Call SK, Pui CH, Razzouk BI: BK virus-induced tubulointerstitial nephritis in a child with acute lymphoblastic leukemia. J Pediatr; 2007 Aug;151(2):215-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BK virus-induced tubulointerstitial nephritis in a child with acute lymphoblastic leukemia.
  • We report a case of BK virus-induced tubulointerstitial nephritis in a child with acute lymphoblastic leukemia.
  • Primary BK virus infection was exacerbated by chemotherapy-induced immunodeficiency.
  • Careful administration of chemotherapy and anti-viral therapy prevented further damage.
  • This diagnosis should be considered in children who experience renal dysfunction during cancer treatment.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurovirol. 1996 Dec;2(6):411-6 [8972423.001]
  • [Cites] Lancet. 1971 Jun 19;1(7712):1253-7 [4104714.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):527-30 [12181409.001]
  • [Cites] J Gen Virol. 2000 Aug;81(Pt 8):1967-73 [10900035.001]
  • [Cites] Transplantation. 2006 Jan 15;81(1):117-20 [16421486.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Clin Infect Dis. 2005 Aug 1;41(3):354-60 [16007533.001]
  • [Cites] Am J Transplant. 2005 Aug;5(8):1997-2004 [15996251.001]
  • [Cites] Pediatr Nephrol. 2005 Jun;20(6):782-5 [15782299.001]
  • [Cites] Leukemia. 1998 Apr;12(4):619-22 [9557622.001]
  • [Cites] Clin Infect Dis. 2005 Feb 15;40(4):528-37 [15712075.001]
  • [Cites] N Engl J Med. 2005 Mar 17;352(11):1157-8 [15784677.001]
  • (PMID = 17643782.001).
  • [ISSN] 1097-6833
  • [Journal-full-title] The Journal of pediatrics
  • [ISO-abbreviation] J. Pediatr.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA021765; None / None / / P30 CA021765-29; United States / NCI NIH HHS / CA / CA 21765; United States / NCI NIH HHS / CA / P30 CA021765-29
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents
  • [Other-IDs] NLM/ NIHMS28072; NLM/ PMC2077844
  •  go-up   go-down


3. Ali SH, Yacoub FM, Al-Matar E: Acute lymphoblastic leukemia presenting as bilateral renal enlargement in a child. Med Princ Pract; 2008;17(6):504-6
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukemia presenting as bilateral renal enlargement in a child.
  • OBJECTIVE: To report a case with early presentation of acute lymphoblastic leukemia (ALL) as bilateral renal masses and renal failure.
  • Accordingly, bone marrow examination was performed, and diagnosis of ALL was made.
  • The patient developed acute renal failure after initiation of chemotherapy, so he received hemodialysis.
  • His renal function normalized and kidney enlargement regressed.
  • [MeSH-major] Acute Kidney Injury / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Child. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Renal Dialysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel.
  • (PMID = 18836283.001).
  • [ISSN] 1423-0151
  • [Journal-full-title] Medical principles and practice : international journal of the Kuwait University, Health Science Centre
  • [ISO-abbreviation] Med Princ Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


Advertisement
4. Mertens R, Granzen B, Vogt K, Melzer H, Mann H: Urine protein analysis by gel electrophoresis and laser densitometry after chemotherapy in pediatric cancer patients. Pediatr Hematol Oncol; 2000 Jul-Aug;17(5):365-74
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urine protein analysis by gel electrophoresis and laser densitometry after chemotherapy in pediatric cancer patients.
  • A common side effect of chemotherapy is reversible or nonreversible nephrotoxicity.
  • A total of 52 pediatric patients were followed during and 63 patients were followed after therapy.
  • During therapy renal damage was recorded in 43% of the leukemia patients, in 56% of nephroblastoma patients, and 75% of patients with other tumors.
  • Three or more months after therapy pathologic patterns were seen in 25% of acute lymphoblastic leukemia patients, in 35% of patients with nephroblastoma, and in 62% of other patients.
  • This method permits a rapid and reliable analysis of urine proteins and is suitable for follow-up tests of renal function during and after chemotherapy.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Electrophoresis, Polyacrylamide Gel / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Proteinuria / diagnosis. Wilms Tumor / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Densitometry / methods. Densitometry / standards. Humans. Kidney Glomerulus / chemistry. Kidney Tubules / chemistry. Lasers. Proteins / analysis. Proteins / chemistry. Renal Insufficiency / chemically induced. Renal Insufficiency / diagnosis. Renal Insufficiency / metabolism

  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10914046.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Proteins
  •  go-up   go-down


5. Suriya OM, Aleem A: Frank hematuria as the presentation feature of acute leukemia. Saudi J Kidney Dis Transpl; 2010 Sep;21(5):940-2
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe two cases of acute leukemia, a 19 year old male with acute lymphoblastic leukemia and a 52 year old male with acute myeloid leukemia, both presenting with gross hematuria.
  • Hematuria in these patients was likely to be due to occult leukemic infiltration of the urinary system, aggravated by thrombocytopenia, as it subsided after starting chemotherapy.
  • [MeSH-major] Hematuria / etiology. Leukemia, Myeloid, Acute / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Blood Cell Count. Bone Marrow Examination. Fatal Outcome. Humans. Leukocyte Count. Male. Middle Aged. Thrombocytopenia / etiology. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Saudi J Kidney Dis Transpl. 2012 Sep;23(5):1088-9 [22982933.001]
  • (PMID = 20814137.001).
  • [ISSN] 1319-2442
  • [Journal-full-title] Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia
  • [ISO-abbreviation] Saudi J Kidney Dis Transpl
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


6. Sorensen K, Levitt GA, Bull C, Dorup I, Sullivan ID: Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study. Cancer; 2003 Apr 15;97(8):1991-8
Hazardous Substances Data Bank. DAUNORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The objective of the current study was to examine the risk factors for progression in severity of anthracycline-induced cardiac dysfunction, thereby providing information that is useful in refining cancer treatment regimes and guiding follow-up.
  • METHODS: Serial echocardiograms were performed on 101 acute lymphoblastic leukemia survivors and 83 Wilms tumor survivors after a mean interval of 6.2 years and 6.7 years since last anthracycline dose, respectively, at first study, and after 10.3 years and 11.1 years, respectively, at second study.
  • The paired data were contrasted with data from 100 normal subjects, and potential correlations with follow-up interval, cumulative dose, cancer diagnosis, gender, age at diagnosis, and growth were explored using univariate and multiple regression techniques.
  • As a group, patients receiving < 240 mg/m(2) showed no deterioration of left ventricular end systolic stress at > 10 years from the end of treatment.
  • [MeSH-major] Antibiotics, Antineoplastic / adverse effects. Daunorubicin / adverse effects. Heart / drug effects. Heart Diseases / chemically induced. Kidney Neoplasms / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Wilms Tumor / drug therapy


7. te Winkel ML, van Beek RD, de Muinck Keizer-Schrama SM, Uitterlinden AG, Hop WC, Pieters R, van den Heuvel-Eibrink MM: Pharmacogenetic risk factors for altered bone mineral density and body composition in pediatric acute lymphoblastic leukemia. Haematologica; 2010 May;95(5):752-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacogenetic risk factors for altered bone mineral density and body composition in pediatric acute lymphoblastic leukemia.
  • BACKGROUND: This study investigates pharmacogenetic risk factors for bone mineral (apparent) density (BM(A)D) and body composition in pediatric acute lymphoblastic leukemia DESIGN AND METHODS: We determined the influence of SNPs in 4 genes (vitamin-D receptor (VDR: BsmI/ApaI/TaqI and Cdx-2/GATA), collagen type I alpha 1 (SpI), estrogen receptor 1 (ESR1: PvuII/XbaI), glucocorticoid receptor (BclI)) on body composition, BM(A)D and fracture risk during dexamethasone-based pediatric acute lymphoblastic leukemia treatment.
  • Body composition and BMD were measured repeatedly during and after treatment using dual energy X-ray absorptiometry.
  • At diagnosis and during therapy, lumbar spine BMD was significantly higher in non-carriers of VDR 5'-end (Cdx-2/GATA) haplotype 3 than in carriers.
  • The other SNPs did not influence BMD or fracture risk during/after treatment.
  • The year after treatment completion, lean body mass increased in non-carriers of ESR1 (PvuII/XbaI) haplotype 3 and decreased in carriers (Delta lean body mass: non-carriers:+0.28SDS, carriers: -0.55SDS, P<0.01).
  • CONCLUSIONS: Only VDR 5'-end (Cdx-2/GATA) haplotype 3 was identified as protective factor against excessive fat gain and as a risk factor for lower lumbar spine BMD during treatment.
  • Carrying ESR1 (PvuII/XbaI) haplotype 3 negatively influenced recovery of lean body mass after pediatric acute lymphoblastic leukemia treatment.
  • [MeSH-major] Body Composition / genetics. Bone Density / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics


8. Malbora B, Avci Z, Alioglu B, Tutar NU, Ozbek N: A case with mature B-cell acute lymphoblastic leukemia and pancreatic involvement at the time of diagnosis. J Pediatr Hematol Oncol; 2008 Jan;30(1):87-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case with mature B-cell acute lymphoblastic leukemia and pancreatic involvement at the time of diagnosis.
  • Pancreatic infiltration with leukemic cells is a rare manifestation of acute lymphoblastic leukemia.
  • We report the clinical and radiologic findings of a 4-year-old boy with mature B-cell acute lymphoblastic leukemia and pancreatic involvement.
  • A computed tomography scan of his abdomen demonstrated diffuse hypodense lesions in the pancreas.
  • Plasma amylase and lipase levels at that time were high, but no signs of hypoglycemia or hyperglycemia were observed.
  • After 2 cycles of chemotherapy, the lesions in his pancreas, liver, and kidney disappeared, and his pancreatitis resolved as well.
  • At 11 months' follow-up, after completion of therapy, the patient continues to be in remission.
  • [MeSH-major] Leukemia, B-Cell / drug therapy. Leukemia, B-Cell / radiography. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / radiography. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiography
  • [MeSH-minor] Acute Disease. Amylases / blood. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Child, Preschool. Diagnosis, Differential. Humans. Kidney Neoplasms / blood. Kidney Neoplasms / drug therapy. Kidney Neoplasms / radiography. Kidney Neoplasms / secondary. Lipase / blood. Liver Neoplasms / blood. Liver Neoplasms / drug therapy. Liver Neoplasms / radiography. Liver Neoplasms / secondary. Male. Pancreatitis / blood. Pancreatitis / drug therapy. Pancreatitis / radiography. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18176191.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.1.1.3 / Lipase; EC 3.2.1.- / Amylases
  •  go-up   go-down


9. Pazur M, Jelić-Puskarić B, Planinc-Peraica A, Vrhovac R, Kardum-Skelin I, Jaksić B: T lymphoblastic leukaemia with an unusual Burkitt lymphoma morphology--a case report. Coll Antropol; 2010 Jun;34(2):675-8
Genetic Alliance. consumer health - Lymphoblastic lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T lymphoblastic leukaemia with an unusual Burkitt lymphoma morphology--a case report.
  • Precursor T-cell acute lymphoblastic leukaemia (T-ALL)/lymphoma (T-LBL) is a neoplasm with cytological features that include blast cells of medium size, high nuclear cytoplasmic ratio and inconspicuous nucleoli, which are usually TdT (Terminal Deoxynucleotidyl Transferase) positive and variably express T-cell markers.
  • A 56-year-old male was hospitalized due to high fever and kidney infection.
  • Bone marrow aspiration revealed 87% and peripheral blood 41% of lymphoblasts with cytoplasmic vacuoles which suggested Burkitt lymphoma (BL) morphology.
  • This excluded Burkitt lymphoma and led to diagnosis of T-ALL.
  • The patient was submitted to two cycles of chemotherapy, autologous stem cell transplantation, and intrathecal chemotherapy, but he died after 10 months because of disease complications (lung aspergillosis and pleural effusion).
  • Beside morphologic criteria, setting correct diagnosis depends on identification of immunophenotype by flow cytometry and cytogenetic-molecular abnormalities.
  • Further improvements in the molecular definition of ALL subtypes, development of new and targeted drugs will improve patient's outcome and prognosis.
  • [MeSH-major] Burkitt Lymphoma / pathology. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Antigens, CD2 / analysis. Bone Marrow / pathology. Cell Nucleus / pathology. Diagnosis, Differential. Fatal Outcome. Humans. Karyotyping. Lymphocytes / pathology. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20698152.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Antigens, CD2
  •  go-up   go-down


10. Suh WM, Wainberg ZA, de Vos S, Cohen AH, Kurtz I, Nguyen MK: Acute lymphoblastic leukemia presenting as acute renal failure. Nat Clin Pract Nephrol; 2007 Feb;3(2):106-10
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukemia presenting as acute renal failure.
  • One week later, he developed acute renal failure requiring hospitalization.
  • DIAGNOSIS: Acute lymphoblastic leukemia, bilateral renal enlargement secondary to leukemic infiltration, acute renal failure, tumor lysis syndrome, and leukemic involvement of the facial nerve.
  • MANAGEMENT: The patient was treated with a modified induction chemotherapy regimen.
  • He was given allopurinol for hyperuricemia and hydrated with alkalized intravenous fluids to prevent uric acid precipitation in the renal tubules.
  • The profound tumor lysis that occurred after the cytotoxic chemotherapy required hemodialysis.
  • [MeSH-major] Acute Kidney Injury / diagnosis. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Tumor Lysis Syndrome / etiology
  • [MeSH-minor] Adult. Biopsy, Needle. Diagnosis, Differential. Emergency Service, Hospital. Follow-Up Studies. Humans. Kidney Function Tests. Male. Renal Dialysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17251998.001).
  • [ISSN] 1745-8331
  • [Journal-full-title] Nature clinical practice. Nephrology
  • [ISO-abbreviation] Nat Clin Pract Nephrol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


11. Hayek M, Srinivasan A: Acute lymphoblastic leukemia presenting with lactic acidosis and renal tubular dysfunction. J Pediatr Hematol Oncol; 2003 Jun;25(6):488-90
Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukemia presenting with lactic acidosis and renal tubular dysfunction.
  • Acute lymphoblastic leukemia (ALL) in children can rarely present with severe lactic acidosis in the absence of a high white blood cell count or other complications.
  • Renal tubular dysfunction with hypercalciuria and hypocalcemia in the absence of pre-existing renal disease or concurrent medications has not been described at presentation in childhood ALL.
  • The authors describe a 7-year-old boy with ALL presenting with severe lactic acidosis and renal tubular dysfunction, both of which were refractory to conventional management and resolved rapidly with appropriate chemotherapy.
  • [MeSH-major] Acidosis, Lactic / diagnosis. Kidney Diseases / diagnosis. Kidney Tubules / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Calcium / blood. Calcium / urine. Child. Diuretics. Humans. Hydrochlorothiazide / therapeutic use. Hypocalcemia / diagnosis. Male. Peritoneal Dialysis. Sodium Chloride Symporter Inhibitors / therapeutic use


12. Kopecna L: Late effects of anticancer therapy on kidney function in children with acute lymphoblastic leukemia. Bratisl Lek Listy; 2001;102(8):357-60
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late effects of anticancer therapy on kidney function in children with acute lymphoblastic leukemia.
  • SUBJECTIVE: The aims of the present study were: to analyse kidney damage as well as the clinical course in children treated for ALL, to determine what type of nephrotoxic damage is most frequent in relation with the used treatment, to determine possible risks of acute and chronic nephropathy of anticancer therapy, to standardise evaluation of kidney function in children after their complex antitumourous treatment has finished.
  • METHODS AND MATERIAL: We examined a group of 36 children (21 boys, 15 girls, average age at diagnosis of ALL 6.9 years)) treated for ALL using the therapeutical protocol ALL BFM 90.
  • The average period after the treatment had finished was 48 month.
  • RESULTS: After finish of cytostatic therapy had 19 patients (52.8%) PU.
  • CONCLUSION: Sensitive laboratory analysis of proteinuria is required for timely detection of the most frequent type of kidney damage in the course of treatment with cytostatics but also other concurrently administered drugs.
  • If there is higher level of glomerular/mixed proteinuria even after the treatment has finished, the patients have to undergo another nephrological monitoring. (Tab. 3, Ref. 20.)
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Kidney / drug effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] 6-Mercaptopurine / administration & dosage. 6-Mercaptopurine / adverse effects. Adolescent. Asparaginase / administration & dosage. Asparaginase / adverse effects. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Cytarabine / administration & dosage. Cytarabine / adverse effects. Daunorubicin / administration & dosage. Daunorubicin / adverse effects. Female. Humans. Infant. Kidney Function Tests. Male. Methotrexate / administration & dosage. Methotrexate / adverse effects. Prednisone / administration & dosage. Prednisone / adverse effects. Vincristine / administration & dosage. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11763664.001).
  • [ISSN] 0006-9248
  • [Journal-full-title] Bratislavské lekárske listy
  • [ISO-abbreviation] Bratisl Lek Listy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; E7WED276I5 / 6-Mercaptopurine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin; AIEOP acute lymphoblastic leukemia protocol
  •  go-up   go-down


13. Nishio H, Sakakibara-Kawamura K, Suzuki T, Utsumi T, Kinoshita S: [An autopsy case of Ph1--positive acute lymphoblastic leukemia with disseminated infection of Fusarium solani]. Kansenshogaku Zasshi; 2002 Jan;76(1):67-71
MedlinePlus Health Information. consumer health - Fungal Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An autopsy case of Ph1--positive acute lymphoblastic leukemia with disseminated infection of Fusarium solani].
  • A 56-year-old woman with Ph1--Positive acute Lymphoblastic Leukemia was admitted to our hospital for induction chemotherapy in June 1999.
  • The patient was presented with a central scotoma of left eye during treatment course and was given diagnosis of endophthalmitis.
  • Thereafter she also developed skin induration and suffered from serious pneumonia.
  • Autopsy was performed, and its specimen revealed the disseminated infection of Fusarium solani (lung, eye, heart, kidney and skin).
  • [MeSH-major] Fusarium. Mycoses / etiology. Philadelphia Chromosome. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11852477.001).
  • [ISSN] 0387-5911
  • [Journal-full-title] Kansenshōgaku zasshi. The Journal of the Japanese Association for Infectious Diseases
  • [ISO-abbreviation] Kansenshogaku Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


14. Zhou Y, Tang Z, Liu ZH, Li LS: Acute lymphoblastic leukemia complicated by acute renal failure: a case report and review of the literature. Clin Nephrol; 2010 Apr;73(4):321-5
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukemia complicated by acute renal failure: a case report and review of the literature.
  • After making a diagnosis of acute lymphoblastic leukemia complicated with acute kidney injury induced by hypercalcemia, CRRT (continued renal replacement therapy) and chemotherapy were used immediately.
  • [MeSH-major] Acute Kidney Injury / complications. Hypercalcemia / complications. Kidney / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications
  • [MeSH-minor] Anemia / complications. Anemia / pathology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20353742.001).
  • [ISSN] 0301-0430
  • [Journal-full-title] Clinical nephrology
  • [ISO-abbreviation] Clin. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 16
  •  go-up   go-down


15. Merkle M, Rupprecht HD: [Lymphoproliferative disease following kidney transplantation]. Dtsch Med Wochenschr; 2005 Jul 15;130(28-29):1691-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lymphoproliferative disease following kidney transplantation].
  • HISTORY AND CLINICAL FINDINGS: A 31-year-old male patient was referred because of a worsening graft function 56 months after an allogenic kidney transplantation for interstitial nephritis.
  • Correction of volume status did not result in an improvement of kidney function.
  • Bacterial or viral enteritis could be excluded as well as a mucosa-associated lymphatic tissue lymphoma (MALT-lymphoma).
  • Shortly thereafter, the patient developed a subileus.
  • INVESTIGATIONS: Kidney biopsy showed a low degree nephrosclerosis and some interstitial fibrosis, but no signs of rejection.
  • Histology showed an EBV-negative, highly aggressive B-blastic lymphoma.
  • DIAGNOSIS: EBV-negative post-transplant lymphoproliferative disease (PTLD).
  • TREATMENT AND COURSE: Because of the advanced lymphoma stage immunosuppressive therapy was reduced and immunochemotherapy according to the CHOP-protocol (cyclophosphamide, doxorubicin, vincristine, prednisone) in combination with rituximab (R-CHOP) was started.
  • After 4 chemotherapy cycles the patient was in complete remission and another 2 therapy cycles were given for consolidation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Kidney Transplantation / adverse effects. Lymphoma, B-Cell / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology. Prednisone / therapeutic use. Vincristine / therapeutic use
  • [MeSH-minor] Abdominal Pain. Adult. Diagnosis, Differential. Diarrhea. Humans. Immunosuppressive Agents / administration & dosage. Immunosuppressive Agents / adverse effects. Male. Remission Induction. Risk Factors

  • Genetic Alliance. consumer health - Kidney Disease.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16003604.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


16. Sinha R, AlAbbas A, Dionne JM, Hurley RM: Simultaneous occurrence of atypical hemolytic uremic syndrome and acute lymphoblastic leukemia: a case report and literature review. Pediatr Nephrol; 2008 May;23(5):835-9
Genetic Alliance. consumer health - Hemolytic uremic syndrome, atypical.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous occurrence of atypical hemolytic uremic syndrome and acute lymphoblastic leukemia: a case report and literature review.
  • Bone marrow examination resulted in a diagnosis of acute lymphoblastic leukemia (ALL).
  • Chemotherapy was started, but she was initially given only steroids (dexamethasone) due to high liver enzymes.
  • She also developed nephrotic-range proteinuria and hypertension.
  • [MeSH-major] Hemolytic-Uremic Syndrome / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications
  • [MeSH-minor] Biopsy. Child, Preschool. Female. Follow-Up Studies. Humans. Kidney Glomerulus / ultrastructure. Microscopy, Electron

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Hemolytic uremic syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Schweiz Med Wochenschr. 1955 Sep 20;85(38-39):905-9 [13274004.001]
  • [Cites] Br Med Bull. 2006;77-78:5-22 [16968692.001]
  • [Cites] Br J Haematol. 2005 Feb;128(3):274 [15667528.001]
  • [Cites] Pediatr Nephrol. 2003 Jul;18(7):703-5 [12750987.001]
  • [Cites] Int J Pediatr Nephrol. 1986 Jul-Sep;7(3):169-71 [3468090.001]
  • [Cites] Semin Thromb Hemost. 2005 Dec;31(6):717-30 [16388423.001]
  • [Cites] Pediatr Nephrol. 2000 Oct;14(12):1118-20 [11045399.001]
  • [Cites] Ann Hematol. 2000 Aug;79(8):452-4 [10985366.001]
  • [Cites] Semin Hematol. 1997 Apr;34(2):140-7 [9109216.001]
  • [Cites] J Clin Pathol. 2004 Jun;57(6):667-9 [15166281.001]
  • [Cites] Thromb Res. 2002 Apr 15;106(2):127-30 [12182911.001]
  • [Cites] J Pediatr. 2003 Mar;142(3):310-7 [12640381.001]
  • [Cites] FASEB J. 1988 May;2(8):2385-95 [2452113.001]
  • [Cites] J Pediatr Hematol Oncol. 2000 Sep-Oct;22(5):483-4 [11037870.001]
  • (PMID = 18188608.001).
  • [ISSN] 0931-041X
  • [Journal-full-title] Pediatric nephrology (Berlin, Germany)
  • [ISO-abbreviation] Pediatr. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


17. Krawczuk-Rybak M, Kuźmicz M, Wysocka J: Renal function during and after treatment for acute lymphoblastic leukemia in children. Pediatr Nephrol; 2005 Jun;20(6):782-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal function during and after treatment for acute lymphoblastic leukemia in children.
  • Renal function tests (cystatin C, serum and urine creatinine, creatinine clearance, serum and urine beta(2)-microglobulin, microalbuminuria, osmolality) were performed in 21 children at the diagnosis and during the treatment for acute lymphoblastic leukemia (ALL) (group I) and in 37 children (group II) treated for ALL 3.9+/-3.7 years before the study.
  • Transitory higher cystatin C values (but in normal range) were observed after methotrexate administration and after the end of treatment.
  • Deteriorated renal function was observed in one child during the treatment (after each protocol) and in five children treated previously for ALL.
  • In conclusion, combined treatment for ALL is not associated with severe or long-term impairment of renal function.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Kidney / physiopathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / physiopathology
  • [MeSH-minor] Case-Control Studies. Child. Creatinine / blood. Creatinine / urine. Cystatin C. Cystatins / blood. Humans. Kidney Function Tests

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Chem. 2002 May;48(5):699-707 [11978596.001]
  • [Cites] Am J Kidney Dis. 1999 Aug;34(2):328-37 [10430982.001]
  • [Cites] Pediatr Hematol Oncol. 1994 Mar-Apr;11(2):165-72 [8204441.001]
  • [Cites] Nephron. 2002 May;91(1):13-20 [12021514.001]
  • [Cites] Clin Chem. 2000 Feb;46(2):193-7 [10657375.001]
  • [Cites] Clin Chem. 2001 Nov;47(11):2055-9 [11673383.001]
  • [Cites] Cancer Chemother Pharmacol. 2003 Mar;51(3):256-60 [12655445.001]
  • [Cites] Pediatr Nephrol. 1998 Sep;12(7):572-5 [9761357.001]
  • [Cites] Med Wieku Rozwoj. 2001 Jul-Sep;5(3 Suppl 1):43-54 [12004151.001]
  • [Cites] Am J Kidney Dis. 2002 Aug;40(2):221-6 [12148093.001]
  • [Cites] Am J Hematol. 2004 Oct;77(2):132-9 [15389822.001]
  • [Cites] Pediatr Nephrol. 1999 Feb;13(2):153-62 [10229006.001]
  • [Cites] Pediatr Nephrol. 2004 Oct;19(10):1145-7 [15258844.001]
  • [Cites] Clin Infect Dis. 1999 Dec;29(6):1402-7 [10585786.001]
  • [Cites] Minerva Pediatr. 1996 May;48(5):193-200 [8926955.001]
  • [Cites] J Infect Dis. 2002 Aug 1;186(3):379-88 [12134234.001]
  • [Cites] Med Toxicol Adverse Drug Exp. 1989 Jan-Feb;4(1):59-72 [2651851.001]
  • [Cites] Clin Chem. 2002 Jul;48(7):1123-6 [12089191.001]
  • [Cites] Acta Paediatr Scand. 1989 Jul;78(4):608-14 [2782077.001]
  • [Cites] J Pediatr Hematol Oncol. 2004 Jun;26(6):336-41 [15167345.001]
  • (PMID = 15782299.001).
  • [ISSN] 0931-041X
  • [Journal-full-title] Pediatric nephrology (Berlin, Germany)
  • [ISO-abbreviation] Pediatr. Nephrol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CST3 protein, human; 0 / Cystatin C; 0 / Cystatins; AYI8EX34EU / Creatinine
  •  go-up   go-down


18. LaRosa C, McMullen L, Bakdash S, Ellis D, Krishnamurti L, Wu HY, Moritz ML: Acute renal failure from xanthine nephropathy during management of acute leukemia. Pediatr Nephrol; 2007 Jan;22(1):132-5
Hazardous Substances Data Bank. Allopurinol .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor lysis syndrome is a potentially life-threatening complication of induction chemotherapy for treatment of lymphoproliferative malignancies.
  • We report a case of oliguric acute renal failure due to bilateral xanthine nephropathy in an 11-year-old girl as a complication of tumor lysis syndrome during the treatment of T-cell acute lymphoblastic leukemia.
  • Xanthine nephropathy should be considered in patients who develop acute renal failure following aggressive chemotherapy with appropriate tumor lysis syndrome prophylaxis.
  • Urine measurements for xanthine could aid in the diagnosis of patients with nephrolithiasis complicating tumor lysis syndrome.
  • [MeSH-major] Acute Kidney Injury / etiology. Nephrolithiasis / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Xanthine / adverse effects
  • [MeSH-minor] Allopurinol / adverse effects. Allopurinol / therapeutic use. Child. Enzyme Inhibitors / adverse effects. Enzyme Inhibitors / therapeutic use. Female. Humans. Tumor Lysis Syndrome / complications. Tumor Lysis Syndrome / drug therapy

  • MedlinePlus Health Information. consumer health - Kidney Stones.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Aktuelle Urol. 2004 Jun;35(3):215-21 [15258855.001]
  • [Cites] Am J Med. 2004 Apr 15;116(8):546-54 [15063817.001]
  • [Cites] Br Med J (Clin Res Ed). 1987 Jun 13;294(6586):1504-5 [3607420.001]
  • [Cites] Pediatr Nephrol. 1989 Oct;3(4):433-7 [2642113.001]
  • [Cites] Arch Intern Med. 1978 Jun;138(6):1017-9 [348139.001]
  • [Cites] Pediatr Nephrol. 1995 Aug;9(4):476-7 [7577413.001]
  • [Cites] Clin Chem. 1987 Dec;33(12):2314-6 [3480085.001]
  • [Cites] N Engl J Med. 1970 Aug 13;283(7):354-7 [5468406.001]
  • (PMID = 17039332.001).
  • [ISSN] 0931-041X
  • [Journal-full-title] Pediatric nephrology (Berlin, Germany)
  • [ISO-abbreviation] Pediatr. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 1AVZ07U9S7 / Xanthine; 63CZ7GJN5I / Allopurinol
  •  go-up   go-down


19. Olgar S, Yetgin S, Cetin M, Aras T, Akhan O: Electrolyte abnormalities at diagnosis of acute lymphocytic leukemia may be a clue for renal damage in long-term period. J Pediatr Hematol Oncol; 2005 Apr;27(4):202-6
MedlinePlus Health Information. consumer health - Kidney Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Electrolyte abnormalities at diagnosis of acute lymphocytic leukemia may be a clue for renal damage in long-term period.
  • The objective of this study was to determine the frequency of electrolyte perturbations and their relationship with leukemic status before and after chemotherapy in patients with acute lymphocytic leukemia.
  • Blood biochemistry, liver and renal function tests, and renal sonograms were examined at diagnosis and during induction therapy in 334 patients.
  • Renal and electrolyte disturbances were then studied in 116 patients between 3 and 110 months after cessation of the St. Jude chemotherapy treatment protocol.
  • Patients with electrolyte disorders at diagnosis were less likely to have tumor lysis syndrome during induction chemotherapy.
  • This may be explained by correction of their electrolyte disorders at the time of diagnosis, which may protect them from tumor lysis syndrome.
  • Hypocalcemia and hyponatremia at the time of diagnosis were found to be significant initial risk factors for renal scan abnormalities and microproteinuria, respectively, during the late therapy period (P < 0.05).
  • Electrolyte abnormalities and renal changes were commonly observed before and after therapy for leukemia.
  • Patients presenting with hypocalcemia and hyponatremia should be examined for microproteinuria and should undergo renal scanning during the late therapy period.
  • [MeSH-major] Kidney Diseases / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Water-Electrolyte Imbalance / etiology
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Female. Glomerular Filtration Rate. Humans. Hyperuricemia / etiology. Hypocalcemia / etiology. Hyponatremia / etiology. Liver Function Tests. Male. Phosphorus Metabolism Disorders / etiology. Proteinuria / etiology. Risk Factors. Time Factors. beta 2-Microglobulin / blood

  • MedlinePlus Health Information. consumer health - Fluid and Electrolyte Balance.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15838391.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / beta 2-Microglobulin
  •  go-up   go-down


20. von Poblozki A, Dempke W, Schmoll HJ: [Carboxypeptidase-G2-rescue in a woman with methotrexate-induced renal failure]. Med Klin (Munich); 2000 Aug 15;95(8):457-60
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Carboxypeptidase-G2-Rescue bei einer Patientin mit Methotrexat-induziertem Nierenversagen.
  • BACKGROUND: Methotrexate (MTX) is a very effective chemotherapeutic drug, widely used in various malignant diseases for systemic therapy.
  • This results in a MTX-accumulation in the body tissue with subsequent massive toxic side effects.
  • CASE REPORT: We report on a 62-year-old woman with acute lymphoblastic leukemia (first diagnosis November 1997) receiving chemotherapy with 2,340 mg methotrexate over 24 hours.
  • [MeSH-major] Acute Kidney Injury / chemically induced. Acute Kidney Injury / drug therapy. Antimetabolites, Antineoplastic / adverse effects. Methotrexate / adverse effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. gamma-Glutamyl Hydrolase / therapeutic use
  • [MeSH-minor] Creatinine / blood. Female. Humans. Infusions, Intravenous. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10985069.001).
  • [ISSN] 0723-5003
  • [Journal-full-title] Medizinische Klinik (Munich, Germany : 1983)
  • [ISO-abbreviation] Med. Klin. (Munich)
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; AYI8EX34EU / Creatinine; EC 3.4.19.9 / gamma-Glutamyl Hydrolase; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


21. Kebaili K, Manel AM, Chapelon C, Taylor P, Philippe N, Bertrand Y: Renal enlargement as presentation of isolated renal relapse in childhood leukemia. J Pediatr Hematol Oncol; 2000 Sep-Oct;22(5):454-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Extramedullary relapses in children with acute lymphoblastic leukemia occur most frequently in the central nervous system and in the testis.
  • In this report, the authors describe a 16-year-old girl with an isolated renal relapse of acute lymphoblastic leukemia after a disease-free interval of 2 years and 8 months.
  • Renal biopsy was required to establish the diagnosis.
  • Treatment consisted of intensive chemotherapy and autologous bone marrow transplantation.
  • [MeSH-major] Kidney / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11037860.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


22. Kopecna L, Dolezel Z, Osvaldova Z, Starha J, Hrstkova H: The analysis of the risks for the development of tumour lysis syndrome in children. Bratisl Lek Listy; 2002;103(6):206-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Acute renal failure (ARF) during the course of cytostatic therapy is a serious complication.
  • TLS comprises a number of metabolic abnormalities (hyperuricemia, hyperphosphatemia, hyperkalemia, azotemia and hypocalcemia) which are associated with lymphoproliferative malignancies following spontaneous or chemotherapy-induced cytolysis.
  • There exist probably no clear prediction for the development of TLS that could enable early detection of manifestation of this severe condition.
  • SUBJECTIVE: Conventional management with aggressive hydration, alkalization of the urine, administration of allopurinol, and the slow introduction of chemotherapy is often unable to prevent metabolic instability and ARF.
  • Recent studies define a subgroup of patients at higher risk of renal failure during induction chemotherapy.
  • ARF was encountered during initial therapy of patients with a lactate dehydrogenase (LDH) index greater than 3.3.
  • RESULTS: Three children needed haemodialysis--2 boys had fully expressed TLS with ARF shortly after starting chemotherapy, in 1 boy the dialysis was indicated because of extreme hyperuricemia and high creatinine level presented before chemotherapy.
  • [MeSH-major] Tumor Lysis Syndrome / diagnosis
  • [MeSH-minor] Acute Kidney Injury / diagnosis. Acute Kidney Injury / etiology. Acute Kidney Injury / therapy. Adolescent. Child. Child, Preschool. Female. Humans. Infant. Lymphoma, Non-Hodgkin / drug therapy. Male. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Renal Dialysis. Retrospective Studies. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12448566.001).
  • [ISSN] 0006-9248
  • [Journal-full-title] Bratislavské lekárske listy
  • [ISO-abbreviation] Bratisl Lek Listy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovakia
  •  go-up   go-down


23. Grigull L, Beier R, Schrauder A, Kirschner P, Loening L, Jack T, Welte K, Sykora KW, Schrappe M: Invasive fungal infections are responsible for one-fifth of the infectious deaths in children with ALL. Mycoses; 2003 Dec;46(11-12):441-6
MedlinePlus Health Information. consumer health - Yeast Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The German ALL-Berlin-Frankfurt-Muenster (BFM) study group is one of the largest cooperation for the treatment of childhood ALL.
  • Between 1995 and 2000, 2021 children with ALL received chemotherapy according to the German BFM 95 protocols (ALL-BFM 95).
  • The underlying risk factors (RF) included neutropenia (seven of nine patients) and steroid medication (nine of nine patients).
  • In six of nine children the fungal infection was progressive despite intravenous antimycotic therapy, three patients received no antifungal therapy, as IFI was not considered.
  • The progression of IFI despite antimycotic therapy illustrates the inherent problems of diagnosis and the need for innovative therapeutic modalities.
  • [MeSH-major] Aspergillosis / mortality. Candidiasis / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications
  • [MeSH-minor] Acute Kidney Injury / complications. Adolescent. Child. Child, Preschool. Germany. Hemolytic-Uremic Syndrome / complications. Humans. Infant. Liver Failure / complications. Neutropenia. Retrospective Studies. Risk Factors. Steroids / adverse effects

  • MedlinePlus Health Information. consumer health - Aspergillosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14641615.001).
  • [ISSN] 0933-7407
  • [Journal-full-title] Mycoses
  • [ISO-abbreviation] Mycoses
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Steroids
  •  go-up   go-down


24. Nizze H, Prall F, Wigger M, Eggers G, Knieling K, Parwaresch R: [Primary renal manifestation in malignant lymphomas and leukemia]. Pathologe; 2003 Oct;24(6):460-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary manifestation of malignant lymphoma and/or leukaemia rarely occurs in the kidney.
  • It can be the cause of a hitherto unexplained acute renal failure or it is incidentally detected as shown in the three cases under report.1.A 68-year-old man was operated on because of a symptomatic tumour in his right kidney.
  • At nephrectomy, a conventional (clear cell) renal cell carcinoma was found simultaneously with an occult mantle cell lymphoma infiltrating the adjacent renal and extrarenal tissue.
  • Clinical follow-up uncovered nodal and bone marrow involvement, so that a primary renal manifestation of mantle cell lymphoma was apparent.2.A 69-year-old man with suspected vertebral metastasis underwent partial renal resection because of a mass in his left kidney.
  • Histologically and immunohistochemically, the renal infiltration was diagnosed as a precursor B-lymphoblastic lymphoma.
  • After chemotherapy and irradiation, leukaemic blood cell counts with 50% lymphoblasts proved a primary renal manifestation of precursor B-lymphoblastic leukaemia/lymphoma.3.A 13-year-old boy presented clinically with renal failure, enlarged kidneys, and normal urinalysis.
  • Renal biopsy showed a diffuse interstitial infiltration with atypical T-lymphoblasts compressing tubules and surrounding preserved glomeruli.
  • Subsequent clinical bone marrow smears presented 60% T-lymphoblasts, so that the final diagnosis of a primary renal manifestation of acute T-lymphoblastic leukaemia of mature thymic cortex type was made.
  • Immediate chemotherapy resulted in total recovery of renal function and bone marrow findings.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Kidney Neoplasms / pathology. Leukemia / pathology. Neoplasms, Second Primary / pathology
  • [MeSH-minor] Adolescent. Aged. Burkitt Lymphoma / pathology. Humans. Leukemia-Lymphoma, Adult T-Cell / pathology. Lymphoma / pathology. Lymphoma / surgery. Lymphoma, B-Cell / pathology. Male. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 1991 Dec;96(6):738-45 [1746490.001]
  • [Cites] AJR Am J Roentgenol. 2003 Feb;180(2):429-31 [12540447.001]
  • [Cites] Am J Surg Pathol. 1987 May;11(5):375-82 [3555131.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] J Urol. 1966 Apr;95(4):485-8 [5326510.001]
  • [Cites] Ann Pathol. 2002 Jun;22(3):222-5 [12410107.001]
  • [Cites] Cancer. 1987 Aug 1;60(3):386-91 [3594375.001]
  • [Cites] Gen Diagn Pathol. 1998 Apr;143(5-6):317-20 [9653914.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1986 Spring;8(1):8-12 [3487255.001]
  • [Cites] J Urol. 1983 Feb;129(2):364-7 [6572731.001]
  • [Cites] Pediatr Med Chir. 1982 Jan-Apr;4(1-2):107-13 [6955776.001]
  • [Cites] Arch Ital Urol Androl. 2002 Mar;74(1):44-7 [12053451.001]
  • (PMID = 14605852.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


25. Bagatell R, Hainstock M, Lowe MC, Barber BJ, Samson RA: The perfect storm: Torsades de Pointes in a child with leukemia. Pediatr Blood Cancer; 2007 Dec;49(7):996-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Torsades de Pointes (TdP) is a life-threatening ventricular arrhythmia that can be associated with metabolic abnormalities, exposure to arrhythmogenic medications, and congenital long-QT syndrome.
  • This report describes a patient with ALL and multiple complications of therapy who developed TdP.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Torsades de Pointes / complications
  • [MeSH-minor] Adolescent. Anti-Bacterial Agents / adverse effects. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Cardiopulmonary Resuscitation. Ecthyma / diagnosis. Ecthyma / drug therapy. Electrocardiography. Electrolytes / administration & dosage. Electrolytes / blood. Female. Follow-Up Studies. Heart Arrest / etiology. Heart Arrest / therapy. Humans. Kidney Diseases / chemically induced. Kidney Diseases / therapy. Long QT Syndrome / complications. Long QT Syndrome / diagnosis. Long QT Syndrome / drug therapy. Remission Induction. Treatment Outcome. Ventricular Premature Complexes / complications. Ventricular Premature Complexes / diagnosis. Ventricular Premature Complexes / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 Wiley-Liss, Inc
  • (PMID = 16333840.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Electrolytes
  •  go-up   go-down


26. Hatakeyama N, Suzuki N, Kudoh T, Hori T, Mizue N, Tsutsumi H: Successful cidofovir treatment of adenovirus-associated hemorrhagic cystitis and renal dysfunction after allogenic bone marrow transplant. Pediatr Infect Dis J; 2003 Oct;22(10):928-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful cidofovir treatment of adenovirus-associated hemorrhagic cystitis and renal dysfunction after allogenic bone marrow transplant.
  • We present a patient who developed hemorrhagic cystitis and renal dysfunction after unrelated bone marrow transplantation.
  • [MeSH-major] Acute Kidney Injury / diagnosis. Adenoviridae / drug effects. Adenoviridae Infections / drug therapy. Bone Marrow Transplantation / adverse effects. Cystitis / drug therapy. Cytosine / administration & dosage. Cytosine / analogs & derivatives. Hematuria / drug therapy. Organophosphonates. Organophosphorus Compounds / administration & dosage
  • [MeSH-minor] DNA, Viral / analysis. Dose-Response Relationship, Drug. Drug Administration Schedule. Follow-Up Studies. Humans. Male. Polymerase Chain Reaction. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Risk Assessment. Transplantation, Homologous / adverse effects. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • Hazardous Substances Data Bank. CIDOFOVIR .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14579818.001).
  • [ISSN] 0891-3668
  • [Journal-full-title] The Pediatric infectious disease journal
  • [ISO-abbreviation] Pediatr. Infect. Dis. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Organophosphonates; 0 / Organophosphorus Compounds; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


27. Gottfredsson M, Steingrímsdóttir H: Disseminated invasive aspergillosis in a patient with acute leukaemia. Acta Biomed; 2006;77 Suppl 2:10-3
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 46-year-old previously healthy woman was diagnosed with acute lymphoblastic leukaemia.
  • The induction phase was complicated by alpha-haemolytic streptococcal bacteremia which responded to antibacterial therapy.
  • Subsequently, the patient developed pneumonie due to Chlamydiapneumoniae which responded to macrolides.
  • Following this infection the patient developed recurrent fever and new pulmonary infiltrates were noted.
  • Bronchoscopy was performed and treatment was administered with liposomal amphotericin B (L-AmB, AmBisome) for two days, but was complicated by acute renal failure.
  • Despite aggressive antifungal therapy the patient developed progressive invasive infection, with central nervous system involvement as well as lesions appearing in the kidneys and liver.
  • The patient died one week following the diagnosis of aspergillosis.
  • [MeSH-major] Amphotericin B / therapeutic use. Antifungal Agents / therapeutic use. Aspergillosis / complications. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / complications
  • [MeSH-minor] Acute Kidney Injury / chemically induced. Anti-Bacterial Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bacteremia / complications. Bacteremia / drug therapy. Chlamydophila Infections / complications. Chlamydophila Infections / drug therapy. Chlamydophila pneumoniae. Doxorubicin / administration & dosage. Drug Resistance, Multiple, Fungal. Drug Therapy, Combination. Echinocandins. Fatal Outcome. Female. Humans. Immunocompromised Host. Liposomes. Lung Diseases, Fungal / complications. Lung Diseases, Fungal / drug therapy. Medical Futility. Methotrexate / administration & dosage. Middle Aged. Neuroaspergillosis / drug therapy. Neuroaspergillosis / etiology. Peptides, Cyclic / administration & dosage. Peptides, Cyclic / therapeutic use. Pneumonia, Bacterial / complications. Pyrimidines / therapeutic use. Streptococcal Infections / complications. Streptococcal Infections / drug therapy. Triazoles / therapeutic use. Vincristine / administration & dosage. Voriconazole

  • Genetic Alliance. consumer health - Aspergillosis.
  • MedlinePlus Health Information. consumer health - Aspergillosis.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • Hazardous Substances Data Bank. CASPOFUNGIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Acta Biomed. 2006;77 Suppl 4:following 33
  • (PMID = 16918060.001).
  • [ISSN] 0392-4203
  • [Journal-full-title] Acta bio-medica : Atenei Parmensis
  • [ISO-abbreviation] Acta Biomed
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antifungal Agents; 0 / Echinocandins; 0 / Liposomes; 0 / Peptides, Cyclic; 0 / Pyrimidines; 0 / Triazoles; 0 / liposomal amphotericin B; 5J49Q6B70F / Vincristine; 7XU7A7DROE / Amphotericin B; 80168379AG / Doxorubicin; F0XDI6ZL63 / caspofungin; JFU09I87TR / Voriconazole; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down






Advertisement